Compare ECF & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ECF | ORMP |
|---|---|---|
| Founded | 1986 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 165.3M |
| IPO Year | N/A | 2010 |
| Metric | ECF | ORMP |
|---|---|---|
| Price | $12.45 | $4.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 16.2K | ★ 487.7K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | 6.42% | ★ 6.51% |
| EPS Growth | N/A | ★ 412.50 |
| EPS | 0.46 | ★ 0.91 |
| Revenue | N/A | ★ $2,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.35 | ★ $4.57 |
| Revenue Growth | N/A | ★ 49.25 |
| 52 Week Low | $10.33 | $1.98 |
| 52 Week High | $13.85 | $5.19 |
| Indicator | ECF | ORMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.59 | 44.36 |
| Support Level | $12.15 | $3.87 |
| Resistance Level | $12.60 | $4.22 |
| Average True Range (ATR) | 0.16 | 0.19 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 27.02 | 9.86 |
Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.